• Home
  • Site Map
  • Contact Us

Alpha-1 Antitrypsin Deficiency Support
facebook
twitter
email

  • About Us
    • About Alpha-1 Awareness
    • Our Booklets
    • Facebook – Our Group
    • Helping Research
    • Newsletters
      • Subscribe to our Newsletters
      • Old Newsletters
    • Alpha1 Scotland
  • Alpha-1
    • Diagnosis
      • Understanding A1AT/AATD
      • Who Should be tested?
      • Videos explaining the condition
    • Treatment
      • Treatment & Therapies
        • Inhalers
        • Nebulisers
        • Antibiotics
        • Healthy Eating
        • Lifestyle
        • Pulmonary Rehabilitation
        • Replacement Therapy
        • Surgical Options
      • Quality Standard of Care
      • Expert Recommendations
  • Children
    • Children with Alpha-1
    • Guide for Schools
    • Alphie Kids Club
  • Info
    • Glossary
    • Links
    • Neswletters
      • Subscribe to our Newsletters
      • Old Newsletters
    • Our Booklets
    • Useful Information
      • Natural Cleaning Products you can make for your home
  • Support Us
    • Car Stickers
    • Collection Boxes, Buckets & Tins
      • Request a Collection Box, Bucket or Tin
      • How to send us the money you have collected
        • Collection Box
        • Collection Bucket
        • Collection Tin
    • How to send us donations
    • Just Giving
      • How to setup a page
      • Just Giving Leader board
    • Fundraising Information
    • Completed Fundraising Events
      • 2018
        • James Balson – 7th April 2018 – Prague Half Marathon
        • Louise Balson – 7th April 2018 – Prague Half Marathon
        • Stephanie Kimble – 15th March 2018 – Milton Keynes Festival of Running 5K
        • Gemma Vivian – 22nd April 2018 – The London Marathon
        • Andrew Stringer – 20th May 2018 – Richmind Marathon
        • Cai Bull – Headshave – July 2018
        • British 10K Run – July 2018
        • Alistair Jagger – 13th July 2018 – London to Paris of bike
        • TrekFest (The Peaks) – September 2018
        • John Gareth Trainor – September 2018 – Cycling the Pyrenees (all of them!)
        • Helen Moss – 27th October 2018 – Eastbourne Beachy Head 10K
      • 2017
        • Paul Amos – 14th May 2017 – Tandem Skydive
        • Cori Ruktanonchai ~ 3rd June 2017 – Stockholm Marathon
        • Paul Seager – 17th June 2017 – 45 Fell Walk
        • British 10K Run – 9th July 2017
        • Sharon Simpson – 2nd September 2017 – 25k Trek Fest (Peak District)
        • Matt Rowley – Runner
        • James Balson – 15th October 2017 – Amsterdam Half Marathon
        • Katie Rigby – 28th October 2017 – Kernow Destroyer
  • Shopping
  • Contact Us



Replacement Therapy

Replacement therapy (also called substitution or augmentation therapy) is a general term for replacing the missing alpha-1 antitrypsin in the bodies of lung or panniculitis affected Alphas.

Currently, all the alpha-1 antitrypsin used is extracted from donated blood plasma. Large amounts of plasma are need to produce sufficient antitrypsin to be used therapeutically. For this reason the treatment is very expensive.

Attempts have been made to produce alpha-1 antitrypsin in other ways but to date these have not been successful.

The method of introducing the antitrypsin into the body is by intravenous infusion. Only 10% to 15% of the drug reaches the lower repiratory tract where it protects the alveoli in the same way as naturally produced alpha1 antitrypsin. Clinical trials are currently underway to test the effectiveness of inhaled antitrypsin. This procedure is simpler than an infusion and possibly more effective (25% to 45% reaches the repiratory tract).

AAT is produced by the following pharmaceutical companies:

Company Product Licensed In
Baxter Aralast & Aralast NP
CSL Behring Zemaira (see note 3)  USA, Brazil, New Zealand
Grifols Trypsone (see note 1) Spain, Mexico, Brazil
Grifols Prolastin (Prolastina, Prolastin C & Pulmolast) USA and others. See note 2
Baxter Glassia
LFB Alfalastin France

Note 1.  Production of Trypsone ceased in 2014.

Note 2.  In the EEA this product is licensed as Prolastin in Austria, Ireland, Italy, Germany, Greece, Poland and Portugal. It is licensed under the name Prolastina in Denmark, Finland, Norway, Spain and Sweden.  In Belgium the licensed product is called Pulmolast.

The existence of a marketing licence does not imply that the product is reimbursed or made generally available to patients who may benefit from it.

Note 3.  In December 2013 CSL Behring submitted a Marketing Authorisation Application to the European Marketing Agency.  The application was based on the results of the RAPID Clinical Trial.  The name of the product was changed from Zemaira to Respreeza.

The EMA Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for Respreeza®, a highly purified alpha-1 protein derived from human plasma, indicated to treat patients with alpha-1 antitrypsin deficiency (AATD). The final decision will be made by the European Council.

Treatment & Therapies

  • Treatment & Therapies
    • Inhalers
    • Nebulisers
    • Antibiotics
    • Healthy Eating
    • Lifestyle
    • Pulmonary Rehabilitation
    • Replacement Therapy
    • Surgical Options
  • Children with Alpha-1
  • Expert Centres

Search Our Website



  • Home Page
  • About Us
  • Helping Research
  • Shopping
  • Regional
  • Understanding AATD
  • Children with Alpha-1
  • Treatment/Therapies
  • Glossary
  • Latest News
  • Links
  • Our Booklets
  • Contact Us

Reg. Charity England and Wales: 1125467, Scotland: SC041100
© 2020 Alpha-1 Awareness
KHS DataSys